Royalty Pharma PLC (RPRX)
| Market Cap | 22.72B |
| Revenue (ttm) | 2.24B |
| Net Income (ttm) | 971.62M |
| Shares Out | 409.34M |
| EPS (ttm) | 1.24 |
| PE Ratio | 30.36 |
| Forward PE | 14.97 |
| Dividend | $0.64 (1.71%) |
| Ex-Dividend Date | Nov 18, 2021 |
| Volume | 1,064,643 |
| Open | 37.57 |
| Previous Close | 37.50 |
| Day's Range | 37.22 - 37.86 |
| 52-Week Range | 34.25 - 52.59 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 51.43 (+37.1%) |
| Est. Earnings Date | Nov 10, 2021 |
About RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 45 marketed therapies an...
Financial Performance
In 2020, Royalty Pharma's revenue was $2.12 billion, an increase of 16.98% compared to the previous year's $1.81 billion. Earnings were $975.04 million, a decrease of -58.48%.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for Royalty Pharma stock is "Buy." The 12-month stock price forecast is 51.43, which is an increase of 37.15% from the latest price.
News
Royalty Pharma to Announce Third-Quarter 2021 Financial Results on November 10, 2021
NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter of 2021 financial results on Wednesday, November 10, 2021 before the U...
Royalty Pharma Declares Fourth-Quarter 2021 Dividend
NEW YORK, Oct. 15, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2021 of $0.17 per Class A ordinar...
Top 3 undervalued US biotech stocks to buy
With the US Q3 earnings season just getting started, there are a few biotech stocks that present an exciting opportunity for value investors. Some of these stocks look significantly undervalued after a ...
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:
Wall Street Journal Creates A Pitch In Favor Of Royalty Pharma
Drug development, both a lucrative and a risky segment. Royalty Pharma plc (NASDAQ: RPRX) offers a middle ground for its investors.
Royalty Pharma (RPRX) Q2 Earnings and Revenues Surpass Estimates
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 1.43% and 0.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Royalty Pharma Q2 Earnings
Shares of Royalty Pharma (NASDAQ:RPRX) rose 3.8% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 26.26% year over year to $0.73, which beat th...
Royalty Pharma Reports Second Quarter 2021 Results
NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipt...
Earnings Preview: Royalty Pharma (RPRX) Q2 Earnings Expected to Decline
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Royalty Pharma to Announce Second-Quarter 2021 Financial Results on August 11, 2021
NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter of 2021 financial results on Wednesday, August 11, 2021 before the U....
Royalty Pharma Declares Third-Quarter 2021 Dividend
NEW YORK, July 16, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2021 of $0.17 per class A ordinary...
Royalty Pharma Announces Pricing of $1.3 Billion of Senior Unsecured Notes, Including $600 Million Social Bond
NEW YORK, July 15, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.3 billion of senior unsecured notes, comprised of the following (collec...
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of June:
Royalty Pharma Insights: Return On Capital Employed
Royalty Pharma (NASDAQ:RPRX) posted a 26.99% decrease in earnings from Q4. Sales, however, increased by 0.18% over the previous quarter to $573.03 million.
MorphoSys to Acquire Constellation Pharma at $34/Share; Enters $2B Strategic Funding with Royalty Pharma
MorphoSys AG (NASDAQ: MOR) has agreed to acquire Constellation Pharmaceuticals Inc (NASDAQ: CNST) for $34/share in cash, representing a total equity value of $1.7 billion. The transaction is expected to...
Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys
NEW YORK and PLANEGG, Germany, June 02, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership...
Royalty Pharma Reports First Quarter 2021 Results
NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts(...
Should You Buy Royalty Pharma (RPRX) Ahead of Earnings?
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Royalty Pharma to Announce First-Quarter 2021 Financial Results on May 11, 2021
NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2021 financial results on Tuesday, May 11, 2021 before the U.S. finan...
Royalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences Indexes
NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a collaboration with MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and serv...
Royalty Pharma Declares Second-Quarter 2021 Dividend
NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2021 of $0.17 per class A share.
SYF or RPRX: Which Is the Better Value Stock Right Now?
SYF vs. RPRX: Which Stock Is the Better Value Option?
Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront
Royalty Pharma plc (NASDAQ: RPRX) has acquired Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) royalty interest in Oxlumo (lumasiran) for an upfront cash payment of $180 million and up to $60 million in c...
Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million
NEW YORK and LEXINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) today announced that R...
Royalty Pharma Buys Royalty Interest In Cabozantinib Products From GSK
Royalty Pharma Plc (NASDAQ: RPRX) has acquired a royalty interest in Cabometyx and Cometriq from GlaxoSmithKline Plc (NYSE: GSK) for an upfront payment of $342 million. Under this transaction's terms, R...